De Villez R L
Arch Dermatol. 1985 Feb;121(2):197-202. doi: 10.1001/archderm.121.2.197.
A randomized double-blind trial of topical minoxidil therapy was carried out on 56 patients with hereditary male pattern baldness. The subjects selected were required to have a discernible balding patch, a minimum of 2.5 cm in diameter on the vertex of the head where the hairs could be counted and photographed. Minoxidil, 1.0 mL, was applied twice a day to the scalp beginning at the balding vertex and spreading centrifugally around the scalp. Cosmetically acceptable hair growth was achieved in 18 patients (32%). The most notable indicators for regrowth of hair were the number of indeterminate hairs initially present, the duration of baldness, and the size of the balding area. No serious systemic or cutaneous side effects were noted.
对56例遗传性男性型秃发患者进行了外用米诺地尔治疗的随机双盲试验。入选的受试者要求头顶有一块可辨认的秃发区,直径至少2.5厘米,此处毛发可计数和拍照。从秃发顶点开始,每天两次将1.0毫升米诺地尔涂抹于头皮,并向头皮周围离心扩散。18例患者(32%)实现了美观上可接受的头发生长。头发生长最显著的指标是最初存在的不确定毛发数量、秃发持续时间和秃发区大小。未观察到严重的全身或皮肤副作用。